|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/16/23 Cell MedX Corp. 10-Q 8/31/23 42:1.9M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Cell Medx Corp. - Form 10-Q SEC Filing HTML 448K
2: EX-31.1 Certification of Principal Executive Officer HTML 16K
3: EX-31.2 Certification of Principal Financial Officer HTML 16K
4: EX-32.1 Certification of Principal Executive Officer HTML 14K
5: EX-32.2 Certification of Principal Financial Officer HTML 14K
11: R1 Document and Entity Information HTML 62K
12: R2 Condensed Consolidated Balance Sheets HTML 83K
13: R3 Condensed Consolidated Balance Sheets - HTML 20K
Parenthetical
14: R4 Condensed Consolidated Statements of Operations HTML 77K
15: R5 Condensed Consolidated Statement of Stockholders' HTML 48K
Deficit
16: R6 Condensed Consolidated Statements of Cash Flows HTML 64K
17: R7 Organization and Nature of Operations HTML 20K
18: R8 Related Party Transactions Disclosure HTML 33K
19: R9 Notes and Advances Payable Disclosure HTML 38K
20: R10 Notes and Advances Payable Disclosure, Current HTML 27K
21: R11 Other Current Assets Disclosure HTML 16K
22: R12 Revenue Disclosure HTML 20K
23: R13 Share Capital Disclosure HTML 21K
24: R14 Related Party Transactions Disclosure: Schedule of HTML 22K
Amounts Due to Related Parties (Tables)
25: R15 Related Party Transactions Disclosure: Schedule of HTML 22K
Transactions with Related Parties (Tables)
26: R16 Notes and Advances Payable Disclosure: Schedule of HTML 29K
Loans and Advances Outstanding to Related Parties
(Tables)
27: R17 Notes and Advances Payable Disclosure, Current: HTML 26K
Schedule of notes and advances payable (Tables)
28: R18 Revenue Disclosure: Schedule of Revenue and HTML 20K
Associated Costs (Tables)
29: R19 Organization and Nature of Operations (Details) HTML 17K
30: R20 Related Party Transactions Disclosure: Schedule of HTML 27K
Amounts Due to Related Parties (Details)
31: R21 Related Party Transactions Disclosure: Schedule of HTML 24K
Transactions with Related Parties (Details)
32: R22 Notes and Advances Payable Disclosure: Schedule of HTML 29K
Loans and Advances Outstanding to Related Parties
(Details)
33: R23 Notes and Advances Payable Disclosure (Details) HTML 63K
34: R24 Notes and Advances Payable Disclosure, Current: HTML 28K
Schedule of notes and advances payable (Details)
35: R25 Notes and Advances Payable Disclosure, Current HTML 18K
(Details)
36: R26 Other Current Assets Disclosure (Details) HTML 18K
37: R27 Revenue Disclosure: Schedule of Revenue and HTML 35K
Associated Costs (Details)
40: XML IDEA XML File -- Filing Summary XML 68K
38: XML XBRL Instance -- cmxc-20230831_htm XML 412K
39: EXCEL IDEA Workbook of Financial Report Info XLSX 47K
6: EX-101.CAL XBRL Calculations -- cmxc-20230831_cal XML 47K
7: EX-101.DEF XBRL Definitions -- cmxc-20230831_def XML 180K
8: EX-101.LAB XBRL Labels -- cmxc-20230831_lab XML 326K
9: EX-101.PRE XBRL Presentations -- cmxc-20230831_pre XML 277K
10: EX-101.SCH XBRL Schema -- cmxc-20230831 XSD 77K
41: JSON XBRL Instance as JSON Data -- MetaLinks 164± 239K
42: ZIP XBRL Zipped Folder -- 0001393905-23-000350-xbrl Zip 91K
| Certification of Principal Executive Officer |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending August 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dwayne Yaretz, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: October 16, 2023
/s/ Dwayne Yaretz
Dwayne Yaretz
Chief Executive Officer
(Principal Executive Officer)
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/16/23 | None on these Dates | ||
| For Period end: | 8/31/23 | |||
| List all Filings | ||||